Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ONCR

Oncorus (ONCR) Stock Price, News & Analysis

Oncorus logo

About Oncorus Stock (NASDAQ:ONCR)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$0.13
$0.20
50-Day Range
$0.01
$0.13
52-Week Range
$0.01
$0.47
Volume
135,947 shs
Average Volume
1.33 million shs
Market Capitalization
$3.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company develops ONCR-021 for the treatment of non-small cell lung cancer, renal cell carcinoma, melanoma, and anaplastic thyroid cancer; and ONCR-788 for the treatment of small cell lung cancer, neuroendocrine prostate, and other neuroendocrine cancers. Oncorus, Inc. was incorporated in 2015 and is headquartered in Andover, Massachusetts.

Remove Ads
Receive ONCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncorus and its competitors with MarketBeat's FREE daily newsletter.

ONCR Stock News Headlines

RFL Rafael Holdings, Inc.
Game Over for Tesla?
Tesla is down 50% from its high... Our research indicates investors are waking up to the fact that Tesla is no longer Musk's #1 priority. His real goal is political power - and his private AI firm xAI. He recently bought over $1 billion worth of AI chips from NVIDIA... And is about to spend $5 billion on yet another data center for xAI.
Comera Life Sciences Holdings Inc
Oncorus Inc Ordinary Shares
ONCR Historical Data
See More Headlines

ONCR Stock Analysis - Frequently Asked Questions

Oncorus, Inc. (NASDAQ:ONCR) announced its quarterly earnings results on Monday, May, 22nd. The company reported ($1.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by $0.48.

Oncorus (ONCR) raised $87 million in an initial public offering on Friday, October 2nd 2020. The company issued 5,800,000 shares at a price of $14.00-$16.00 per share. Jefferies, Evercore ISI and Piper Sandler acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncorus investors own include Enterprise Products Partners (EPD), Aeglea BioTherapeutics (AGLE), Athenex (ATNX), Cheniere Energy (LNG), Atreca (BCEL), Fiserv (FI) and Brigham Minerals (MNRL).

Company Calendar

Last Earnings
5/22/2023
Today
3/31/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ONCR
Fax
N/A
Employees
64
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$2.33 per share
Price / Book
0.05

Miscellaneous

Free Float
21,633,000
Market Cap
$3.29 million
Optionable
Optionable
Beta
3.60
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:ONCR) was last updated on 3/31/2025 by MarketBeat.com Staff
From Our Partners